Gao L, Lin Q. Immune-related gene characteristics: A new chapter in precision treatment of gastric cancer. World J Gastrointest Oncol 2024; 16(8): 3372-3375 [PMID: 39171166 DOI: 10.4251/wjgo.v16.i8.3372]
Corresponding Author of This Article
Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, No. 8 Huizhan Avenue, Renqiu 062552, Hebei Province, China. billhappy001@163.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2024; 16(8): 3372-3375 Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3372
Immune-related gene characteristics: A new chapter in precision treatment of gastric cancer
Lei Gao, Qiang Lin
Lei Gao, Department of Medical Imaging, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu 062552, Hebei Province, China
Qiang Lin, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu 062552, Hebei Province, China
Author contributions: Gao L and Lin Q contributed to this paper; Lin Q designed the overall concept and outline of the manuscript; Gao L wrote the draft of the manuscript; Gao L and Lin Q contributed to the writing and editing the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, No. 8 Huizhan Avenue, Renqiu 062552, Hebei Province, China. billhappy001@163.com
Received: February 13, 2024 Revised: April 25, 2024 Accepted: May 20, 2024 Published online: August 15, 2024 Processing time: 176 Days and 14.1 Hours
Abstract
Gastric cancer ranks as the sixth most prevalent cancer worldwide. In recent research within the realm of gastric cancer treatment, the identification and application of immune-related genetic features have emerged as groundbreaking advancements. The study by Ma et al, which developed a prognostic model based on 10 genes, categorizes patients into high and low-risk groups to predict their responsiveness to immune checkpoint inhibitor therapy. This research underscores the potential of immune-related genes as biomarkers for personalized treatment, offering insights into tumor mutation burden and immune phenotype scores. We advocate for further validation, understanding of biological mechanisms, and integration of diverse datasets to enhance the model's predictive accuracy and clinical application, marking a significant step towards personalized and precise treatment for gastric cancer.
Core Tip: In the study conducted by Ma et al, a prognostic model for gastric cancer was developed, leveraging 10 pivotal immune-related genes to differentiate patients into high and low-risk categories. This model aims to refine immunotherapy strategies, enhancing the personalization and precision of treatments. Such discoveries hold the promise of introducing novel biomarkers for the personalized medical treatment and immunotherapy of gastric cancer, underscoring the critical importance of further research and validation.
